MindWalk Introduces B Cell Llama™ to Accelerate Nanobody Discovery for Next-Generation Therapies
MindWalk Holdings Corp a bio-native artificial intelligence company focused on advanced drug discovery, has announced the launch of B Cell Llama™, a specialized platform designed to discover VHH nanobodies. These single-domain antibody fragments are increasingly viewed as powerful building blocks for emerging therapeutics such as bispecific antibodies, multispecific biologics, and CAR-T cell therapies.
Demand for these advanced treatments is growing rapidly. Industry analysts project that bispecific antibody therapies alone could generate nearly $50 billion in annual sales by 2030, while the broader cell therapy sector is expected to add tens of billions more. MindWalk developed B Cell Llama™ to help research partners take advantage of this expanding market by providing higher-quality starting materials and AI-guided insights throughout the discovery process.
According to Dr. Jennifer Bath, Chief Executive Officer of MindWalk, VHH nanobodies address a long-standing challenge in drug engineering. Traditional antibody formats can be difficult to combine into stable and effective multispecific medicines. Nanobodies, however, are smaller, structurally stable, and easier to assemble into complex therapeutic designs.
B Cell Llama™ extends MindWalk’s flagship B Cell Select® technology by focusing on the unique biology of llama-derived antibodies. While B Cell Select® isolates antibody-producing B cells from immunized rabbits, the new platform captures VHH nanobodies directly from immunized llamas. This provides access to naturally evolved single-domain antibodies that can serve as flexible building blocks for advanced therapeutics.
Dr. Bath noted that the platform’s distinguishing feature is the integration of MindWalk’s LensAI™ technology across the entire discovery pipeline. The AI system can help identify optimal targets even before immunization begins, evaluate antibody candidates based on predicted biological function, and simulate complex multispecific constructs digitally before they are produced in the laboratory. This approach aims to reduce development time while improving the probability that promising candidates will advance successfully.
The launch of B Cell Llama™ is supported by peer-reviewed scientific research. A study published in the 2026 issue of Biomacromolecules, a journal of the American Chemical Society, demonstrated the potential advantages of modular VHH nanobody design. The research was conducted by MindWalk in collaboration with Eindhoven University of Technology and Radboud University Medical Center as part of a grant-funded project.
The study produced several notable findings. First, researchers observed that assembling nanobodies into multivalent structures significantly enhanced their potency. When displayed in multivalent formats, the nanobodies achieved sub-nanomolar potency, delivering effects roughly 10 to 25 times stronger than the same molecules used in a single-binding format.
Second, the research showed that modular reconfiguration of nanobodies could help overcome resistance. Scientists constructed a trivalent VHH molecule that successfully neutralized variants that had escaped both monovalent nanobody formats and two existing approved antibody therapies. The result suggests that rearranging the same molecular building blocks into new configurations can restore activity when single-agent treatments lose effectiveness.
A third finding hinted at a possible immune-system benefit. VHH-nanoparticle complexes were preferentially absorbed by immune cells associated with long-term immune memory. This observation raises the possibility that certain nanobody designs might not only neutralize harmful targets but also help train the immune system to recognize them in the future.
The study also produced an insight relevant to AI-driven drug discovery. Researchers found that the nanobody with the strongest measured binding affinity showed no functional activity. This highlights a key limitation in traditional antibody discovery methods, which often prioritize binding strength when ranking candidates. In reality, strong binding does not always translate into therapeutic effectiveness.
MindWalk’s LensAI™ platform is designed to address this issue by focusing directly on predicted biological function rather than relying solely on binding metrics. By combining experimental data with machine learning models, the system aims to identify molecules that are more likely to demonstrate real therapeutic impact.
B Cell Llama™ builds upon the infrastructure of B Cell Select®, one of several technologies within MindWalk’s broader platform ecosystem. Together, these technologies have already supported the advancement of more than 15 therapeutic molecules into clinical development.
The new platform is part of MindWalk’s broader bio-native AI strategy, which applies artificial intelligence to biological systems in order to accelerate drug discovery. The company is currently advancing programs in multiple therapeutic areas.
Among them are treatments targeting all four serotypes of dengue, which are progressing toward manufacturing; a universal influenza program aimed at a conserved cross-strain viral target; and research into GLP-1-based longevity therapies involving a novel dual-pathway treatment approach. The company is also developing a program targeting ALK-1, with potential applications in oncology and rare diseases.
Source link :https://www.businesswire.com/
